Search Within

Kenneth Ho-Ming Yu

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (5)
Groups
  1. Center for Pancreatic Cancer Research (15)
  2. Department of Medicine (15)
  3. Gastrointestinal Oncology Service (15)
  4. Hematologic Malignancies, Division of (15)
  5. Solid Tumor Oncology Division (15)
  6. Survivorship Research (10)

More Groups

People
  1. Eileen O'Reilly (14)
  2. Anna Varghese (10)
  3. Geoffrey Ku (10)
  4. Jia Li (9)
  5. Alice Zervoudakis (7)
  6. Joanne Chou (7)

More People

Years
  1. 2023 (3)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (4)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. Annals of Oncology (2)
  3. Cancer (2)
  4. BMC Cancer (1)
  5. Gastric Cancer (1)
  6. JAMA - Journal of the American Medical Association (1)
Publishers
  1. American Society of Clinical Oncology (8)
  2. Oxford University Press (2)
  3. Wiley Blackwell (2)
  4. American Medical Association (1)
  5. Biomed Central Ltd (1)
  6. Springer (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation
    Meeting Abstract

    Yu, K. H.; Weekes, C. D.; Chen, Y. B. A.; Glazier, J. A.; Glazier, A.; Dahi, P.; Giralt, S.; O'Reilly, E. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Meeting Abstract

    Keane, F.; Park, W.; Varghese, A.; Balogun, F.; Yu, K.; El Dika, I.; Khalil, D.; Kelsen, D. P.; Reidy-Lagunes, D.; Ku, G. Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer
    Journal Article

    Yu, K. H.; Park, J.; Mittal, A.; Abou-Alfa, G. K.; El Dika, I.; Epstein, A. S.; Ilson, D. H.; Kelsen, D. P.; Ku, G. Y.; Li, J.; more...
    Cancer (2022)

    Fulltext@MSK | Save
  • Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes
    Journal Article

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Park, W.; Bandlamudi, C.; Berger, M. F.; Kelsen, D. P.; Suehnholz, S. P.; Chakravarty, D.; more...
    Cancer (2021)

    Fulltext@MSK | Save
  • Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK)
    Meeting Abstract

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Yu, K. H.; Varghese, A. M.; Park, W.; Zervoudakis, A.; Li, J.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Park, W.; Wong, W.; Yu, K. H.; Varghese, A. M.; Riaz, N.; Balachandran, V. P.; El Dika, I. H.; Raj, N. P.; Khalil, D.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
    Journal Article

    Mondaca, S.; Margolis, M.; Sanchez-Vega, F.; Jonsson, P.; Riches, J. C.; Ku, G. Y.; Hechtman, J. F.; Tuvy, Y.; Berger, M. F.; Shah, M. A.; more...
    Gastric Cancer (2019)

    Fulltext@MSK | Save
  • Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis
    Meeting Abstract

    Yu, K. H.; Mantha, S.; Tjan, C.; Kaufmann, E. S.; Brenner, R.; Lowery, M. A.; Ku, G. Y.; Raj, N. P.; Shcherba, M.; Goldberg, Z.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save